Details

Autor(en) / Beteiligte

• CHALASANI, Naga
• MANZARBEITIA, Cosme
• LOPEZ-TALAVERA, Juan Carlos
• FERENCI, Peter
• VOGEL, Wolfgang
• FONTANA, Robert J
• VOIGT, Michael
• RIELY, Caroline
• MARTIN, Paul
• TEPERMAN, Lewis
• JIAO, James

Titel

Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials

Ist Teil von

• Hepatology (Baltimore, Md.), 2005-02, Vol.41 (2), p.289-298

Ort / Verlag

Hoboken, NJ: Wiley

Erscheinungsjahr

2005

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• There is currently no effective treatment for recurrent hepatitis C after orthotopic liver transplantation (OLT). We therefore performed two randomized, controlled trials--a prophylaxis trial and a treatment trial--to evaluate the safety and efficacy of peginterferon alfa-2a in patients who had undergone OLT. The prophylaxis trial enrolled 54 patients within 3 weeks after OLT, and the treatment trial enrolled 67 patients 6 to 60 months after OLT. In each trial, patients were randomized to treatment with once weekly injections of 180 microg peginterferon alfa-2a or no antiviral treatment for 48 weeks and were followed up for 24 weeks thereafter. Peginterferon alfa-2a treated patients had significantly lower hepatitis C virus RNA levels and more favorable changes in hepatic histological features compared with untreated controls. However, only 2 treated patients in the prophylaxis trial (8%) and 3 in the treatment trial (12%) achieved a sustained virological response. In the prophylaxis trial, 8 patients (31%) in the peginterferon alfa-2a group and 9 (32%) in the untreated group were withdrawn prematurely; whereas in the treatment trial, 10 patients (30%) in the peginterferon alfa-2a group and 6 (19%) in the untreated group were withdrawn prematurely. The incidence of acute rejection was similar in the treated and untreated groups in both the prophylaxis (12% vs. 21%; P = .5) and treatment (12% vs. 0%; P = .1) trials. In conclusion, peginterferon alfa-2a treatment for 48 weeks is safe and tolerable and offers some efficacy in the post-OLT setting. Randomized controlled studies are needed to establish the efficacy of pegylated interferon and ribavirin in patients who have undergone OLT.